Lancet Public Health. 2025 Apr;10(4):e309-e320. doi: 10.1016/S2468-2667(25)00045-3.ABSTRACTBACKGROUND: Over the past two decades, the Italian National Health Service has been gradually decentralised, with Italy's 21 regional governments now responsible for managing their health services. This change
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):277-278. doi: 10.1016/S2213-8587(25)00057-9.NO ABSTRACTPMID:40148064 | DOI:10.1016/S2213-8587(25)00057-9
Lancet Public Health. 2025 Apr;10(4):e321-e332. doi: 10.1016/S2468-2667(25)00044-1. Epub 2025 Mar 20.ABSTRACTBACKGROUND: Given Japan's rapidly ageing demographic structure, comprehensive and long-term evaluations of its national and subnational health progress are important to inform public health p
Lancet Glob Health. 2025 Mar 19:S2214-109X(25)00021-X. doi: 10.1016/S2214-109X(25)00021-X. Online ahead of print.ABSTRACTUndernutrition-the leading risk factor for tuberculosis worldwide-is associated with impaired immunity, more extensive disease, delayed sputum conversion, and worse treatment outc
Lancet Rheumatol. 2025 Mar 17:S2665-9913(25)00031-1. doi: 10.1016/S2665-9913(25)00031-1. Online ahead of print.ABSTRACTVascular ultrasound can be useful in the diagnostic investigation of patients with suspected giant cell arteritis. The clinical overlap between polymyalgia rheumatica and giant cell
No abstractLancet Diabetes Endocrinol. 2025 Mar 12:S2213-8587(25)00071-3. doi: 10.1016/S2213-8587(25)00071-3. Online ahead of print.NO ABSTRACTPMID:40088920 | DOI:10.1016/S2213-8587(25)00071-3
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):e7. doi: 10.1016/S2213-8587(25)00065-8. Epub 2025 Mar 8.NO ABSTRACTPMID:40064192 | DOI:10.1016/S2213-8587(25)00065-8
Lancet Diabetes Endocrinol. 2025 Mar 4:S2213-8587(24)00371-1. doi: 10.1016/S2213-8587(24)00371-1. Online ahead of print.ABSTRACTBACKGROUND: Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipien
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):e7. doi: 10.1016/S2213-8587(25)00056-7. Epub 2025 Mar 5.NO ABSTRACTPMID:40056926 | DOI:10.1016/S2213-8587(25)00056-7
No abstractLancet Diabetes Endocrinol. 2025 Mar 4:S2213-8587(24)00399-1. doi: 10.1016/S2213-8587(24)00399-1. Online ahead of print.NO ABSTRACTPMID:40056924 | DOI:10.1016/S2213-8587(24)00399-1
Lancet Diabetes Endocrinol. 2025 Feb 27:S2213-8587(24)00377-2. doi: 10.1016/S2213-8587(24)00377-2. Online ahead of print.ABSTRACTBACKGROUND: Data on tirzepatide in Asian patients with obesity are limited. This study aimed to gain a better understanding of tirzepatide for treatment of Japanese patien
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):265-267. doi: 10.1016/S2213-8587(24)00373-5. Epub 2025 Feb 26.NO ABSTRACTPMID:40023187 | DOI:10.1016/S2213-8587(24)00373-5
Lancet Diabetes Endocrinol. 2025 Apr;13(4):294-306. doi: 10.1016/S2213-8587(24)00346-2. Epub 2025 Feb 26.ABSTRACTBACKGROUND: Bodyweight loss is associated with type 2 diabetes remission; however, the quantitative relationship between the degree of bodyweight loss and the likelihood of remission, aft
Lancet Glob Health. 2025 Mar;13(3):e459-e466. doi: 10.1016/S2214-109X(24)00520-5.ABSTRACTBACKGROUND: The incidence of type 2 diabetes in sub-Saharan Africa is expected to increase, but few longitudinal studies have characterised its risk factors. This study aimed to determine the incidence of type 2
No abstractLancet Diabetes Endocrinol. 2025 Mar;13(3):e6. doi: 10.1016/S2213-8587(25)00006-3.NO ABSTRACTPMID:40015811 | DOI:10.1016/S2213-8587(25)00006-3
No abstractLancet Diabetes Endocrinol. 2025 Mar;13(3):176-177. doi: 10.1016/S2213-8587(25)00030-0.NO ABSTRACTPMID:40015809 | DOI:10.1016/S2213-8587(25)00030-0
No abstractLancet Diabetes Endocrinol. 2025 Mar;13(3):175-176. doi: 10.1016/S2213-8587(25)00029-4.NO ABSTRACTPMID:40015808 | DOI:10.1016/S2213-8587(25)00029-4
Lancet Respir Med. 2025 Feb 21:S2213-2600(24)00369-2. doi: 10.1016/S2213-2600(24)00369-2. Online ahead of print.ABSTRACTBACKGROUND: Extracorporeal membrane oxygenation (ECMO) for COVID-19 was thoroughly assessed during the first pandemic wave, but data on subsequent waves are limited. We aimed to in
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):e7. doi: 10.1016/S2213-8587(25)00051-8. Epub 2025 Feb 21.NO ABSTRACTPMID:39993395 | DOI:10.1016/S2213-8587(25)00051-8
Lancet Diabetes Endocrinol. 2025 Feb 17:S2213-8587(24)00372-3. doi: 10.1016/S2213-8587(24)00372-3. Online ahead of print.ABSTRACTTreating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes gu
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):e7. doi: 10.1016/S2213-8587(25)00032-4. Epub 2025 Feb 17.NO ABSTRACTPMID:39978367 | DOI:10.1016/S2213-8587(25)00032-4
Lancet Diabetes Endocrinol. 2025 Apr;13(4):321-332. doi: 10.1016/S2213-8587(24)00362-0. Epub 2025 Feb 14.ABSTRACTBACKGROUND: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myo
Lancet Infect Dis. 2025 Feb 13:S1473-3099(24)00749-7. doi: 10.1016/S1473-3099(24)00749-7. Online ahead of print.ABSTRACTCandida species are the predominant cause of fungal infections in patients treated in hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms o
No abstractLancet Diabetes Endocrinol. 2025 Apr;13(4):264-265. doi: 10.1016/S2213-8587(25)00003-8. Epub 2025 Feb 7.NO ABSTRACTPMID:39929223 | DOI:10.1016/S2213-8587(25)00003-8
